Compare iShares Core US Aggregate Bond ETF (AGG) vs Baxter International Inc (BAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs Baxter International Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.32, while Baxter International Inc trades at $27.61 (market cap $14.36B). The key difference: Baxter International Inc pays a 0.14% dividend while iShares Core US Aggregate Bond ETF pays none, and Baxter International Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | BAX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $28.35 |
52-Week Low | $97.24 | $15.80 |
Market Cap | — | $14.36B |
Enterprise Value | — | $21.88B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $97.6, up 0.17% on the day, with a neutral technical signal and bearish moving averages. Recent news highlights institutional accumulation and bond ETF inflows amid fluctuating Treasury yields. The ETF offers consistent dividends, with the latest payments scheduled for 2026.
Outlook remains tied to interest rate trends and inflation data, presenting income stability but facing pressure from rising yields. Key risks include Fed policy shifts and geopolitical impacts on oil prices, while institutional buying signals confidence in fixed-income appeal.
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
